From an October AFR article: "QScan owns more than 70 clinics and makes about $70 million a year at the EBITDA line. Bidders were told to expect more than 10 per cent annual growth through the forecast period."
Someone has previously mentioned D&A would be decent in this business. EBIT @ 10x = well below $700m being contemplated.
Consider how much Quadrant has invested into QScan + bolt-ons + its return requirements and you can determine whether they're talking EBITDA or EBIT in the press.
It is rare to see EBIT numbers without being explicitly disclosed by the reporter (in my humble opinion).
IFT Price at posting:
$5.26 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)